Literature DB >> 19014964

Degradation products analysis of an Fc fusion protein using LC/MS methods.

Da Ren1, Gayathri Ratnaswamy, Jill Beierle, Michael J Treuheit, David N Brems, Pavel V Bondarenko.   

Abstract

The following analytical methods have been used to identify and quantify degradation products in an E. coli expressed human immunoglobulin G Fc fusion protein in both liquid and lyophilized forms: two-dimensional AEX/RP/MS, limited proteolysis followed by LC/MS, and tryptic digestion followed by LC/MS/MS. After aging in a potassium phosphate pH 7.0 buffer for 3 months at 29 degrees C, peptide map analysis revealed that asparagine N78 (N297 according to Edelman sequencing) of the CH2 domain was the most rapidly deamidated site in the molecule probably due to the lack of the N-linked glycan on this asparagine, but this deamidation can be prevented under properly formulated conditions. This is the first report on the rate of deamidation on N297 of an IgG molecule without glycosylation. The active protein portion of the Fc fusion protein contains two methionine residues that are potentially susceptible to oxidation. Limited proteolysis was employed to cleave the active protein portion and measure the amount of oxidation. LC/MS analysis identified that the liquid sample aged at 29 degrees C for 3 months produced 40% oxidation, while the control sample contained only 4% oxidation on the active protein. In contrast to the aged liquid sample, the aged lyophilized sample showed no increase of deamidation or oxidation after storage at 37 degrees C for 8 months.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19014964     DOI: 10.1016/j.ijbiomac.2008.10.006

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  4 in total

1.  Multivariate analysis of the sequence dependence of asparagine deamidation rates in peptides.

Authors:  Andrew A Kosky; Vasumathi Dharmavaram; Gayathri Ratnaswamy; Mark Cornell Manning
Journal:  Pharm Res       Date:  2009-09-09       Impact factor: 4.200

Review 2.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

3.  Antibody characterization using novel ERLIC-MS/MS-based peptide mapping.

Authors:  Jing Zhen; John Kim; Ying Zhou; Ervinas Gaidamauskas; Shyamsundar Subramanian; Ping Feng
Journal:  MAbs       Date:  2018-09-11       Impact factor: 5.857

4.  Effect of protein structure on deamidation rate in the Fc fragment of an IgG1 monoclonal antibody.

Authors:  Sandipan Sinha; Lei Zhang; Shaofeng Duan; Todd D Williams; Josef Vlasak; Roxana Ionescu; Elizabeth M Topp
Journal:  Protein Sci       Date:  2009-08       Impact factor: 6.725

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.